Free shipping on all orders over $ 500

BMS-8 

Cat. No. M28797
BMS-8  Structure
Size Price Availability Quantity
5mg USD 95  USD95 In stock
10mg USD 165  USD165 In stock
25mg USD 345  USD345 In stock
50mg USD 550  USD550 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1.

Chemical Information
Molecular Weight 494.42
Formula C27H28BrNO3
CAS Number 1675201-90-7
Form Solid
Solubility (25°C) DMSO 83.33 mg/mL (ultrasonic)
Storage 4°C, protect from light
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Alberto Pla-López, et al. Int J Mol Sci. Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents

[2] Paweł Niedziałkowski, et al. Bioelectrochemistry. Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode

[3] Guillaume Marquis-Gravel, et al. EuroIntervention. Drug-coated stents versus bare metal stents in Academic Research Consortium-defined high bleeding risk patients

[4] Eun-Hye Kim, et al. Int J Mol Sci. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions

[5] B-C Zhang, et al. Intern Med J. Clinical outcome of drug-eluting versus bare-metal stents in patients with calcified coronary lesions: a meta-analysis

Related PD-1/PD-L1 Products
Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.

Erfonrilimab

Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.

Benmelstobart

Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: BMS-8  supplier, PD-1/PD-L1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.